Medicare AdvantageCoverageMedium impact
Liquid Biopsy - Medicare Advantage (Revised)
Humana·Oncology, Hematology, Pathology·Medicare Advantage
We identified it
Aug 4, 2026
Summary
Humana Medicare Advantage has issued a revised policy on Liquid Biopsy, a blood test that detects circulating tumor cells or tumor-derived DNA. This is a definitional/clarification update for a diagnostic test commonly used in oncology. The billing team must verify coverage criteria, prior authorization requirements, and applicable billing codes for liquid biopsy testing under this plan.
Action Required
Immediately: Contact Humana Medicare Advantage at the policy source (https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a5908cd) or your account representative to obtain the FULL policy document, not just the summary. The billing team must clarify: (1) Which specific CPT codes (e.g., 81520, 81521, 81522, or proprietary lab codes) are covered under this revised policy; (2) Whether prior authorization is required before ordering liquid biopsy tests; (3) Any medical necessity criteria or documentation requirements; (4) Coverage limitations or frequency restrictions. Update billing software rules and encounter workflows once full policy details are available. Do NOT bill liquid biopsy tests without confirmation of coverage and authorization requirements—claims may be denied for using wrong codes or lacking prior auth.